Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Long-Term Debt Issuances (2022 - 2023)

Historic Long-Term Debt Issuances for Seres Therapeutics (MCRB) over the last 2 years, with Q2 2023 value amounting to $103.4 million.

  • Seres Therapeutics' Long-Term Debt Issuances changed N/A to $103.4 million in Q2 2023 from the same period last year, while for Sep 2024 it was $103.4 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $103.4 million for FY2023, which is 27447.66% up from last year.
  • Per Seres Therapeutics' latest filing, its Long-Term Debt Issuances stood at $103.4 million for Q2 2023.
  • In the past 5 years, Seres Therapeutics' Long-Term Debt Issuances registered a high of $103.4 million during Q2 2023, and its lowest value of $27.6 million during Q1 2022.